Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology
WJ Gradishar, MS Moran, J Abraham… - Journal of the National …, 2024 - jnccn.org
Breast cancer is treated with a multidisciplinary approach involving surgical oncology,
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …
Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy
Tamoxifen reduces the rate of breast cancer recurrence by approximately a half. Tamoxifen
is metabolized to more active metabolites by enzymes encoded by polymorphic genes …
is metabolized to more active metabolites by enzymes encoded by polymorphic genes …
[HTML][HTML] Hormonal therapy in breast cancer: a model disease for the personalization of cancer care
S Puhalla, S Bhattacharya, NE Davidson - Molecular oncology, 2012 - Elsevier
The treatment of breast cancer is driven by subtype classification, of which the assessment
of hormone receptor status is one of the important determinants of therapy. The use of …
of hormone receptor status is one of the important determinants of therapy. The use of …
Treatment of estrogen receptor-positive breast cancer
F Lumachi, A Brunello, M Maruzzo… - Current medicinal …, 2013 - ingentaconnect.com
Estrogen receptor (ER) expression is the main indicator of potential responses to endocrine
therapy (ET), and approximately 70% of human breast cancers (BCs) are hormone …
therapy (ET), and approximately 70% of human breast cancers (BCs) are hormone …
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
CM Kelly, DN Juurlink, T Gomes, M Duong-Hua… - Bmj, 2010 - bmj.com
Objective To characterise whether some selective serotonin reuptake inhibitor (SSRI)
antidepressants reduce tamoxifen's effectiveness by inhibiting its bioactivation by …
antidepressants reduce tamoxifen's effectiveness by inhibiting its bioactivation by …
Breast cancer version 3.2014
WJ Gradishar, BO Anderson, SL Blair… - Journal of the National …, 2014 - jnccn.org
Breast cancer is the most common malignancy in women in the United States and is second
only to lung cancer as a cause of cancer death. The overall management of breast cancer …
only to lung cancer as a cause of cancer death. The overall management of breast cancer …
Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract
Different antidepressant drugs are currently used for the treatment of depression in cancer
patients, such as second-generation antidepressants and, recently, the extracts of …
patients, such as second-generation antidepressants and, recently, the extracts of …
Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review
Abstract At least 25–30% of patients with cancer and an even higher percentage of patients
in an advanced phase of illness meet the criteria for a psychiatric diagnosis, including …
in an advanced phase of illness meet the criteria for a psychiatric diagnosis, including …
Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women
Objectives: Although clinical trials have demonstrated the benefit of adjuvant hormonal
therapy for hormone receptor-positive breast cancer, it is not known whether poor …
therapy for hormone receptor-positive breast cancer, it is not known whether poor …
CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark
Abstract Background Cytochrome P450 2D6 (CYP2D6) inhibition reduces the concentration
of 4-hydroxylated tamoxifen metabolites, but the clinical relevance remains uncertain …
of 4-hydroxylated tamoxifen metabolites, but the clinical relevance remains uncertain …